China ulcerative colitis market, by Drug Therapy (5-Aminosalicylates, Monoclonal Antibodies, Steroids, Immunomodulators, and Antibiotics), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, a

China ulcerative colitis market, by Drug Therapy (5-Aminosalicylates, Monoclonal Antibodies, Steroids, Immunomodulators, and Antibiotics), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. This disease can affect people of any age. The major symptoms of this disease include diarrhea, belly pain/cramps, bleeding from the rectum, also other indications include sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan, and blood test. If ulcerative colitis persists for over eight years or longer, it may lead to colon cancer.

The people having mild symptoms of this disease can be cured by over the counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps to prevent colon cancer. The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system.

Market Dynamics

The growing prevalence of ulcerative colitis, increase in lifestyle related risk factors, emergence of biosimilars, ongoing clinical trials, rise in drug approvals and launches, increasing R&D expenditure and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the China ulcerative colitis market over the forecast period.

For instance, in May 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for XELJANZ (tofacitinib) to treat adult patients with moderate to severe active ulcerative colitis.

Key features of the study:

• This report provides in-depth analysis of the China ulcerative colitis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the China ulcerative colitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include AbbVie Inc., Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen, BRISTOL-MYERS SQUIBB, Athos Therapeutics, Inc., Finch Therapeutics Group, Inc., Tillotts Pharma AG, and Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The China ulcerative colitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the China ulcerative colitis market

Detailed Segmentation:

• China Ulcerative Colitis Market, By Drug Therapy:
• 5-Aminosalicylates
• Monoclonal Antibodies
• Steroids
• Immunomodulators
• Antibiotics
• China Ulcerative Colitis Market, By Route of Administration:
• Oral
• Parenteral
• China Ulcerative Colitis Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Company Profiles
• AbbVie Inc.*
• Company Overview
• Material Portfolio
• Financial Performance
• Key Highlights
• Market Strategies
• Celltrion Healthcare
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche AG
• Arena Pharmaceuticals
• Takeda Pharmaceuticals Company Ltd.
• GlaxoSmithKline Plc.
• Eli Lilly and Company
• AstraZeneca
• Pfizer Inc.
• Amgen
• BRISTOL-MYERS SQUIBB
• Athos Therapeutics, Inc.
• Finch Therapeutics Group, Inc.
• Teva Pharmaceutical Industries Ltd.
• Tillotts Pharma AG

“*” marked represents similar segmentation in other categories in the respective section.